Identification and safe storage of look-alike, sound-alike medicines in automated dispensing cabinets

Henna Karoliina Ruutiainen 1,2, Miia Marjukka Kallio, 2,3 Sini Karoliina Kuutinen 2,3

ABSTRACT

Objectives Automated dispensing cabinets (ADCs) are used in hospitals to improve medication safety and decrease costs. However, ADCs do not completely eliminate the risk of mistakes between look-alike, sound-alike (LASA) medicines. The aim of this study was to identify the characteristics of LASA medicines and determine the factors related to their safe storage in ADCs.

Methods The medication selection of one hospital pharmacy’s ADC located in an intensive care unit was observed. The study consisted of five parts: a determination of criteria to identify LASA medications, an analysis of an ADC’s inventory reports, assessment of the storage of identified LASA medicines, a visual observation of the medicine packages stored in the same storage compartment and qualitative analysis of the medication-use process from prescribing a medicine to removing it from an ADC.

Results Approximately 70% (n=355/488) of the ADCs selection had a LASA risk with at least one product. Moreover, 20% (n=84/355) of the LASA medicines identified were high-alert medications. Approximately 16% (n=58/355) of the identified LASA medicines were stored unsafely close to at least one other LASA medicine. Less than 4% (n=13/355) of the LASA medicines were unsafely stored high-alert medications.

Conclusions ADCs reduce the risks of LASA medication errors when used correctly, but automation can also increase them, for example, when placing multiple LASA medicines in the same storage compartment. Attention should be paid to the identification and safe storage of LASA medicines to promote safe use of ADCs in hospitals.

INTRODUCTION

In healthcare, most patient safety incidents are caused by medication errors.1 Look-alike, sound-alike (LASA) medicines can become confused with each other in any step of the medication-use process, exposing patients to incorrect medicine or wrong route errors.2,4–7 LASA names are medicine names that look or sound the same as other medicine names when written or spoken. Look-alike medicine packaging refers to medicine containers or primary packaging that looks like that of another medicine. LASA errors can lead to serious adverse events especially when high-alert medications are involved.4,8,9 High-risk situations arising from LASA naming, similar packaging and labelling could be prevented by ensuring that these are checked thoroughly during prescription, transcription, procurement, storage and dispensing.1,4,7,8

Medication safety.4,9–11 They represent a decentralised medicine system in which the storage and distribution of medicines take place at the ward.11,12 ADCs improve medication safety by facilitating the control of medicine consumption through computer-controlled storage and tracing properties, for example, via a barcode-scanning technology and by preventing the entrance of outsiders into the ADC’s dispensary.2,14 Furthermore, ADCs bring economic savings due to the increased inventory turn rate reducing the amount of expired medicines and by saving nursing time.11,15

When used correctly, ADCs provide a safe storage environment for LASA medicines.11,12,9,13 ADCs are also an important part of closed-loop medication management systems, where technology is used to support safe medication administration, identify risks of error and document each phase of the medication-use process.2,11,13,16 International guidelines promoting the safe storage of LASA medicines have been created, for example, by the Institute of Safe Medication Practices (ISMP).9 Even though ADCs have been found to improve medication safety when used correctly, they are also associated with new types of risk, such as mix-ups between LASA medications.9,11,12 Although LASA medicines have been explored in previous studies (eg, Lebanon et al 2012, Shah et al and Zacher et al 2016), none of them have focused on LASA risks related to ADCs.17,18 The aim of this study is to identify the characteristics of LASA medicines, as well as to determine the factors related to their safe storage in the ADCs.

METHODS

Study design

This mixed-methods study consisted of five parts: a determination of criteria to identify LASA medications, an analysis of an ADC’s inventory reports to identify LASA names, assessment of the storage of identified LASA medicines, a visual observation of the medicine packages stored in the same storage unit to identify look-alike medicine packaging and a qualitative analysis of the medication-use process from prescribing a medicine to removing it from an ADC to evaluate the potential for confusions. A flowchart of the study is presented in figure 1. The mixed-methods study followed the SQUIRE 2.0 statement where applicable.18

Study setting

The study was conducted in HUS Pharmacy, the hospital pharmacy at Helsinki University Hospital (HUS) in Finland. Since 2018, HUS Pharmacy has provided an ADC service to wards to reduce costs and time from manual medication distribution and...
Determination of criteria to identify look-alike, sound-alike (LASA) medicines following the Institute of Safe Medication Practice’s recommendations.\(^{9,21}\)

**Qualitative analysis** of automated dispensing cabinet (ADC) inventory reports to identify LASA groups based on similar medicine names

- generic names, brand names, identification numbers (Vnr)
- identification of high-alert medications

**Analysis of the ADC stock location reports to identify how the LASA groups were stored**

**Visual observation** to identify similar looking packages stored in same location

- similar outer and inner packages
- identification of high-alert medications

**Qualitative analysis** of medication-use process and the identified LASA risks

---

**Figure 1** Flowchart of the study.

to reallocate pharmaceutical resources to more clinical work. At the time of the study in February 2020, there was a total of 75 ADCs in HUS.

HUS Pharmacy uses Pyxis MedStation ES\(^{TM}\) ADCs leased from Becton Dickinson Finland Oy. The cabinets can be assembled from different storage units or compartments to meet the varying needs of the wards. Most of the medicines are stored in locked open-access compartments (eg, matrix drawers) that can store up to 90 products. Even though each product is placed individually on a numbered site, the configuration allows the user to remove any product located in the same drawer (eg, another similar-looking package). High-alert medications, such as opioids, can be placed in their own individual secured compartments (locked- lidded CUBIE\(^{TM}\) pockets).\(^9\)

Products are restocked to the ADCs by using the generic or brand name, medicine identification number or barcode, the latest being the most commonly recommended practice.\(^9\) Medicines identification number, in Finland called the Nordic article number or Vnr number, can also be used in the search. A Vnr number is a six-digit identification code that is mandatory for marketing authorised medicines in the Nordic countries.\(^{19}\) Pharmacy technicians are primarily responsible for the restocking and inventory of the ADCs. At the time of this study, ADCs at HUS were operated using overrides, which means medicines are taken from the ADC without an integrated patient profile.\(^{9,12}\) Medicines are searched and removed from the ADCs using the generic name or brand name of the product, which creates a possibility for mix-ups between two medicines with similar names.

**Study method**

The medication selection of one of HUS Pharmacy’s ADCs located in an intensive care unit was observed in February 2020 to identify LASA medications. The ADC consisted of a main cabinet with five CUBIE\(^{TM}\) drawers and one matrix drawer, a seven-drawer auxiliary cabinet with seven matrix drawers, one double-column eight-door cabinet, a single-column four-door cabinet and two refrigerators. At the time of the study, there was a total of 488 products in the ADC.

In the first part, the criteria used to identify LASA medicines were created according to the recommendations of the ISMP (figure 1 and table 1).\(^9,20\) The identified LASA medicines formed LASA groups that consisted of at least two different products. Medicinal products with the same generic or brand name were considered as LASA medicines if they had a different strength or package size. LASA groups containing at least one high-alert medication defined by ISMP or a high-alert medication list of HUS were identified (table 1).\(^9,21\)

In the second part, an analysis of the inventory reports was performed to identify LASA medicines based on the active substances, generic names or brand names (figure 1). The ADC’s inventory reports were available in alphabetical order for both generic names (in Finnish) and brand names. The identified LASA medicines were extracted to a table in the Microsoft Excel spreadsheet program alphabetically according to the active substances to form LASA groups (online supplemental table 1). Following this, products were identified by their Nordic article numbers.

---

**Table 1** Criteria used to identify LASA medicines in analysis of inventory reports and visual observation of the storage units

<table>
<thead>
<tr>
<th>LSA risk</th>
<th>Data source</th>
<th>Criteria</th>
<th>Identification of high-alert medications*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of active substance or generic name</td>
<td>ADC inventory reports</td>
<td>At least the first five (5) letters must be the same or 3–4 identical letters and otherwise similar spelling(^{20})</td>
<td>Yes</td>
</tr>
<tr>
<td>Brand name</td>
<td>ADC inventory reports</td>
<td>At least the first five (5) letters must be the same or 3–4 identical letters and otherwise similar spelling(^{20})</td>
<td>Yes</td>
</tr>
<tr>
<td>The appearance of the package</td>
<td>Visual observation</td>
<td>In the same storage unit close to each other. At least the colouring or size, or both, of the outer packaging look alike. If other LASA risks are noted, the inner packaging was also acknowledged</td>
<td>Yes</td>
</tr>
<tr>
<td>Nordic article number or other identification number</td>
<td>ADC inventory reports</td>
<td>Considered if there is at least one of the aforementioned LASA risks and at least the first four (4) of the numbers are the same or the series of numbers are otherwise similar</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*Based on the ISMP\(^9\) and the HUS Helsinki University Hospital’s intensive care units high-alert medication lists.

ADC, automated dispensing cabinet; LASA, look-alike, sound-alike.
In the third part, safe storage of the identified LASA groups was evaluated (figure 1). ADC stock location reports were analysed to determine whether the products were properly stored apart, offering improvements where needed, or if there were other observations. If the LASA medicines were located close to each other in the same storage unit or with storage site numbers that could be easily confused (eg, 1 and 10), the placement was considered not safe. Other observations were made if the only option was to store LASA medicines in the same storage unit due to lack of space, but they were clearly separated from each other (eg, medicines located in the refrigerator).

In the fourth part, the ADC’s storage units were inspected one by one and LASA medicines were observed according to the outer packaging (figure 1). The inner packages of LASA medicines identified in the first part and stored close to each other were examined. The inner packaging was also noted if the outer package was missing. The LASA medicines found according to the appearance of the packaging were photographed and listed (online supplemental figure 1). The study did not consider LASA medicines required placement correction due to LASA risk. This was approximately 12% (n=58/488) of the ADC’s selection. Of the 15 LASA groups identified in the observational part of the study, six LASA groups were not found in the analysis of inventory reports, giving us a total of 181 LASA groups (table 2). Positively, over 80% (n=147/181) of LASA groups were stored safely apart from each other. Only eight groups including high-alert medications were unsafely stored. The ADC contained seven HUS Pharmacy-made 100 mL oral suspensions stored in the refrigerators. The suspensions are bottled into identical brown glass bottles and separated by different coloured labels. Two of them (hydrochlorothiazide 5 mg/mL and hydrocortisone 5 mg/mL) were stored unsafely.

The size of the LASA groups varied from two different products to as many as 11 products (eg, paracetamol preparations). Over half (n=105/173) of the LASA groups by name involved a LASA risk related to both generic and brand names (table 2). In addition, the same set of LASA groups included almost 90% (n=17/19) of similar Nordic article number pairs. Examples of the identified LASA risks are presented in table 3. It was noted that some pharmaceutical manufacturers use look-alike packaging for medicines belonging to the same therapeutic class (figure 2) or also having LASA medicines by name (table 3).

A total of 16% (n=58/355) of the identified LASA medicines required placement correction due to LASA risk. This was approximately 16% (n=58/355) of the identified LASA medicines. The obser-

RESULTS
Approximately 70% (n=355/488) of the ADC’s medicine selection were associated with LASA risk with at least one other product (online supplemental table 1 and figure 1). Up to 20% (n=84/355) of the identified LASA medicines were high-alert medications. The LASA groups by name contained 352 products, of which 81 were high-alert medications. The observational section included 30 products in total, including three LASA medicines that were not identified in the inventory report analysis (online supplemental figure 1). The number of identified LASA groups, including the amount of high-alert medication groups and the storage information, is presented in table 2.

The size of the LASA groups varied from two different products to as many as 11 products (eg, paracetamol preparations). Over half (n=105/173) of the LASA groups by name involved a LASA risk related to both generic and brand names (table 2). In addition, the same set of LASA groups included almost 90% (n=17/19) of similar Nordic article number pairs. Examples of the identified LASA risks are presented in table 3. It was noted that some pharmaceutical manufacturers use look-alike packaging for medicines belonging to the same therapeutic class (figure 2) or also having LASA medicines by name (table 3).

A total of 16% (n=58/355) of the identified LASA medicines required placement correction due to LASA risk. This was approximately 16% (n=58/355) of the ADC’s selection. Of the 15 LASA groups identified in the observational part of the study, six LASA groups were not found in the analysis of inventory reports, giving us a total of 181 LASA groups (table 2). Positively, over 80% (n=147/181) of LASA groups were stored safely apart from each other. Only eight groups including high-alert medications were unsafely stored. The ADC contained seven HUS Pharmacy-made 100 mL oral suspensions stored in the refrigerators. The suspensions are bottled into identical brown glass bottles and separated by different coloured labels. Two of them (hydrochlorothiazide 5 mg/mL and hydrocortisone 5 mg/mL) were stored unsafely.

The analysis of the medication-use process revealed numerous steps where confusion can occur between similar names, packaging, medicine identification numbers and dosage forms (table 4). In particular, risks were observed if several LASA medicines were stored in the same storage unit. The features

### Table 2 Number of identified look-alike, sound-alike (LASA) medicine groups, their storage and the amount of LASA groups involving high-alert medications

<table>
<thead>
<tr>
<th>LASA RISK</th>
<th>LASA groups involving high-alert medications n (%)</th>
<th>LASA groups not involving high-alert medications n (%)</th>
<th>All LASA groups n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic names</td>
<td>18 (38)</td>
<td>37 (29)</td>
<td>55 (31)</td>
</tr>
<tr>
<td>• Nordic article number pairs*</td>
<td>0 (0)</td>
<td>2 (15)</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Brand names</td>
<td>4 (8)</td>
<td>11 (9)</td>
<td>15 (9)</td>
</tr>
<tr>
<td>• Nordic article number pairs*</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Generic and brand names</td>
<td>26 (54)</td>
<td>79 (62)</td>
<td>105 (60)</td>
</tr>
<tr>
<td>• Nordic article number pairs*</td>
<td>6 (100)</td>
<td>11 (85)</td>
<td>17 (89)</td>
</tr>
<tr>
<td>Total</td>
<td>48 (100)</td>
<td>127 (100)</td>
<td>175 (100)</td>
</tr>
<tr>
<td></td>
<td>6 (100)</td>
<td>13 (100)</td>
<td>19 (100)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LASA risk</th>
<th>Visual observation</th>
<th>Storage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outer package</td>
<td>1 (17)</td>
<td>41 (80)</td>
</tr>
<tr>
<td>Inner package†</td>
<td>3 (50)</td>
<td>8 (16)</td>
</tr>
<tr>
<td>Outer and inner package</td>
<td>2 (33)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Total</td>
<td>6 (100)</td>
<td>51 (100)</td>
</tr>
<tr>
<td>Storage was safe</td>
<td>41 (82)</td>
<td>106 (82)</td>
</tr>
<tr>
<td>Storage was unsafe</td>
<td>8 (15)</td>
<td>20 (15)</td>
</tr>
<tr>
<td>Observations with the storage</td>
<td>2 (4)</td>
<td>4 (3)</td>
</tr>
<tr>
<td>Total</td>
<td>51 (100)</td>
<td>130 (100)</td>
</tr>
</tbody>
</table>

*Similar Nordic article numbers were observed from only the LASA groups identified by name and are already included in the total LASA group amount.
†Similar inner packages were observed only based on the unsafely storage LASA groups identified by name.
of the ADC can contribute risks, for example, in the case of a long generic or brand name, as the name does not fit completely on the small-sized screen when searching the product (online supplemental figure 1). Shortages of medicines and changes in the medication selection had contributed to situations where several products under different brand names, such as paracetamol preparations Pamol F 250 mg and Pinex 250 mg, could be stored in the same storage site.

**DISCUSSION**

To the best of our knowledge, this is the first study to identify LASA medications combining both analysis of LASA generic and brand names with visual observation. In addition, we assessed the possible consequences of the identified LASA risks in the ADC during the different phases of the medication-use process. According to our findings, as much as 70% of the ADC’s products were associated with LASA risk. Around 20% of the identified LASA drugs were also high-alert medications, when the consequences of the mix-ups can be particularly serious. The observed LASA risks were mix-ups between similar generic or brand names (or both), the identification numbers and the outer or inner packaging. One group of LASA medicines could include multiple risks (eg, similar names and outer packaging) which increases the risk of confusion. Although the ADCs are a part of prospective risk management with numerous safety features, human factors associated with LASA risks can still contribute medication errors.

LASA names have been studied, for example, by Lebanova et al (2012) and Shah et al (2016) examining orthographic and phonetic similarities. The results were conforming: the LASA medication pairs shared at least three letters, mostly situated in the prefix. In addition, LASA medicines have been identified from incident reporting systems’ reports. However, the diversity of incident reporting systems and the varying definition of LASA medicines in them have posed problems. As a solution, efforts have been made to develop a computer-assisted classification and recognition system to search for potential LASA medicines that could be used to prevent errors. Electronic systems for recognising LASA medicines could also increase practitioners’ LASA medicine knowledge.

According to the guidelines of the ISMP, the LASA risk can be significantly reduced if at least the first five letters of the name are used when searching a medicine from an ADC. However, we found that despite the use of the first five letters, the LASA risk was present, especially with products that have an identical name. As one of the solutions is to prevent LASA risks, it has been recommended to use Tall Man lettering to emphasise the differences in the spelling of names by using capital letters (eg, tetraCAINe and tetraCOSACTIDE, DAUNOrubicin and DOXOrubicin). To the best of our knowledge, Tall Man letters are not commonly used on pharmaceutical industry labels in Europe. Nevertheless, it would be possible to use Tall Man lettering on the display of an ADC.

Although ADCs increase the safety of the medication-use process, they can contribute to oversights because of an excessive sense of safety. At the time of the study, medication order integration to the ADCs was not in place and overrides were used, and the medication dispenser should pay attention to a separate medication list. Integration of the patient’s medicine profile to the ADC makes it possible to limit the variety of medicines that could be removed using overrides. The integration of the medicine profile does not eliminate prescribing errors related to LASA medicines, which is why ready-made electronic prescription templates and clinical decision support systems are recommended. Barcodes should be used throughout the whole medication-use process to verify the right medicine.

In addition, pre-administration double-checks can be used, but the poor quality of these procedures can also cause medication errors, while especially mix-ups involving LASA medicines can easily be overlooked.

The main defence against the LASA risks when removing the medicine from the ADC is to carefully plan the sites where the medicines are stored. It is strongly recommended to store the LASA medicines in entirely different storage compartments if possible. In this study, one storage compartment did not

---

Table 3  Examples of identified LASA medicines and the associated risk of confusion

<table>
<thead>
<tr>
<th>LASA risk</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Name of active substance or generic name | When searching “ket” (in English equivalent to “ket”), the ADC suggests the following generic names and products, each on its own line:  
- *Kefotaksimi* (cefotaxime) Cefotaxim Eberth 0.5G  
- *Kefatsidimi* (ceftazidime) Ceftazidim Fresenius Kabi 1 and 2g  
- *Keftraksoni* (ceftiraxone) Ceftriaxion Fresenius Kabi 1g and 2g  
- *Kefuroksimi* (cefoxime) Cefuroxim MIP Pharma 750 mg and 1500 mg  
Products can be mixed with each other on the basis of the generic names (as well as brand names), all are antibiotics |
| Brand name | When searching “sul”, the ADC suggests the following products by the brand name, each on its own line:  
- *Sulco-Cortef* 100mg and 250mg (hydrocortisone)  
- *Sulovit* (water-soluble vitamins)  
- *Sul-Medrol* 40 mg and 125 mg and 500 mg and 1 g (methylprednisolone) |
| The appearance of the package | Next to each other are Vitalisip Infant and Nutrintrace, both infusion concentrates for nutritional support and high-alert medications. Similar-sized white and purple package |
| Nordic article number or other identification number | Tacrolimus preparations Prograf 1 mg and Prograf 5 mg Nordic article numbers are 376509 and 376593. Only the last two digits differ. The preparations are high-alert medications |

*Based on the ISMP and the HUS Helsinki University Hospital’s intensive care units high-alert medication lists.*

ADC, automated dispensing cabinet; LASA, look-alike, sound-alike.

---

Figure 2  Similar outer packaging of antibiotic tablet preparations manufactured by Ratiopharm GmbH.
outperform the others in terms of the most significant LASA risk. If safe separate placement of LASA medicines is not possible, auxiliary labelling of LASA medicines and their storage compartments may be required in order to attract attention.7–9 13 The LASA risks should be considered, especially when restocking medicines to an ADC, when changing the medication selection, and preferably already when the medicine selection is being planned. ADCs can also be programmed with automated alerts regarding LASA risks, for example, when removing high-alert LASA medicine.8 26 Due to similar packaging, particular attention should be paid to pharmaceutical products compounded in hospital pharmacies.27

The study covered only one ADC at HUS and the ward’s clinical specialty had an influence on the selection of medicines. The study was conducted at an intensive care unit, where the selection of medicines was large (488 products), but differed in characteristics, for example in terms of the fewer orally administered tablets and the diversity of intravenous products compared with other wards. However, we found it necessary to limit the research material because of the time-consuming research method. It is important that the identification of LASA medicines is performed on a ward-by-ward basis so that attention can be paid to these specific features. LASA medicine identification is especially important on wards that have patients requiring special attention (eg, paediatric departments and intensive care units).8 28 This feature was also considered in this study. The results can be applied when creating LASA medication lists and guidelines related to ADCs’ inventory planning and safe use. Qualitative analysis of inventory reports and observation of storage sites were performed manually, so the possibility of errors leaving LASA medications unnoticed cannot be ruled out. However, the mixed-methods study was considered necessary, as there is limited research on the topic, and the study was intended to provide a preliminary overview of the issue.

Inventory reports were available in alphabetical order by brand name or similar sounding or looking generic name, brand name or identification number. Hearing or reading the prescription incorrectly, Adrenaline 1 mg/mL is confused with Lidocain c. adrenaline 10 mg/mL+10 µg/mL. The error is facilitated if the indication is not known.

### Table 4

<table>
<thead>
<tr>
<th>Process phase</th>
<th>Risks*</th>
<th>Examples of LASA risks</th>
</tr>
</thead>
</table>
| Written or verbal prescription from a doctor | Similar names:  
► Abbreviations are used  
► The verbal order is not repeated  
► The written order does not specify the intended use  
► Inadvertently selecting a LASA medicine instead of the desired medicine | An epinephrine injection solution is needed at a strength of 1 mg/mL (high-alert medication) |
| The product is searched from the ADC using the generic name, brand name or identification number | Similar names:  
► The medicine is searched using less than five letters  
► The ADC contains several products with the same name that become confused between them | Searching a product using less than the first five letters, for example, “adre” → the ADC offers seven different epinephrine products. |
| The product is selected and the dose is entered | Similar identification numbers or Nordic article numbers | Searching “adrenalinii” (“adenalin”) → the ADC offers four different epinephrine products. A high risk of choosing the wrong preparation, for example, Adrenaline 0.1 mg/mL instead of Adrenaline 1 mg/mL, Adrenaline 0.1 mg/mL (5 mL) and Noradrenaline Hospira 1 mg/mL (4 mL) (noradrenaline or norepinephrine). Can be confused with each other as the products have a LASA risk caused by similar names and Nordic article numbers 536797 and 576876. |
| Repeated if several medicines for the same patient is needed | Similar names or packaging: there are LASA medicines in the same storage unit | In the same refrigerator at similar storage sites (eg, 1 and 11) several different epinephrine preparations are placed side by side, for example Adrenaline 1 mg/mL (1 mL) and Adrenaline 0.1 mg/mL (5 mL). LASA risk based on the similar packaging, strength and names |
| Guided by the ADC, the required amount of product is removed from the package and the package is put back in place | The outer package is missing → the ampoules look alike  
Due to a change in the medication selection or due to a shortage of medicines, the appearance or a brand name of the needed product has changed → higher risk to select a LASA medicine |

*The table does not take a stand on other possible medication errors, such as misdiagnosis or dose calculation errors.

LASA, look-alike, sound-alike.
they were stored in the same storage compartment. Therefore, more products from the studied ADC could be considered as LASA medicines. However, LASA medicines were identified in several different ways by using largely different methods: a visual observation and a qualitative analysis of inventory reports based on the international list of LASA medicines. There are differences in literature if the products are LASA medicines only when the names resemble each other. If considered as aforementioned, the removal of the visual observation section would change the results for the better as all the founded LASA medicines were found to be stored unsafely. Furthermore, in literature, medical errors caused by confusions between similar strengths have been considered as LASA errors (eg, different concentrations of propofol). This study can be used as a basis for further research related to the topic and, for example, the characteristics of errors related to the identified LASA medicines or the level of harm caused by LASA medicine confusions could be studied.

CONCLUSIONS

Approximately 70% of the ADC’s medication selection was identified as LASA medicines based on similar names or packaging. LASA medicines are a high-alert medication group of their own. In addition, around 20% of the recognised LASA medicines were identified as high-alert medications based on, for example, pharmacological properties. ADCs reduce the LASA risks when used correctly, but can also increase them, for instance, when placing multiple LASA medicines in the same storage compartment. Automation can also increase risk for errors due to a sense of security. It is important to promote the safe use of the ADCs and to raise awareness of LASA medications.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval HUS Pharmacy granted research permission for this study. Ethics committee approval was not required because the study did not manage patient data.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID ID
Henna Karoliina Ruutialainen http://orcid.org/0000-0002-2184-3088

REFERENCES
